Skip to main content
Fig. 4 | BMC Medicine

Fig. 4

From: Construction of a risk stratification model integrating ctDNA to predict response and survival in neoadjuvant-treated breast cancer

Fig. 4

Mutation landscape of ctDNA. A Overview of ctDNA status, clinical characters, and response at baseline (T0). B Proportion of ctDNA-positive and ctDNA-negative patients at baseline (T0) according to clinical characteristics. C Proportion of ctDNA-positive and ctDNA-negative patients at different time points. D Comparing the difference of ctDNA fraction at different time points. P values were calculated using one-way analysis of variance

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us